Reuters
17 Sept 2026, 18:41 UTC · 1h ago
Verdict
Headline leans bullish. We score RARE +1.00 across one claim.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
The U.S. FDA approved Ultragenyx's gene therapy for a rare, fatal disease on Thursday.
NewFDA said on Thursday
So whatApproval transforms the asset from a R&D cost center to a revenue generator starting in FY2026.
More positive than 98% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 98% of ticker scores this week
The FDA has approved the company's gene therapy for a rare, fatal disease.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
4h ago
+12.6%
Price agrees with the score
$14.50 vs $12.88 close before publication (Sep 16) · not market-adjusted
RARE chart →
